Cargando…
Genotype-Dependent Efficacy of a Dual PI3K/mTOR Inhibitor, NVP-BEZ235, and an mTOR Inhibitor, RAD001, in Endometrial Carcinomas
The PI3K (phosphatidylinositol-3-kinase)/mTOR (mammalian target of rapamycin) pathway is frequently activated in endometrial cancer through various PI3K/AKT-activating genetic alterations. We examined the antitumor effect of NVP-BEZ235—a dual PI3K/mTOR inhibitor—and RAD001—an mTOR inhibitor—in 13 en...
Autores principales: | Shoji, Keiko, Oda, Katsutoshi, Kashiyama, Tomoko, Ikeda, Yuji, Nakagawa, Shunsuke, Sone, Kenbun, Miyamoto, Yuichiro, Hiraike, Haruko, Tanikawa, Michihiro, Miyasaka, Aki, Koso, Takahiro, Matsumoto, Yoko, Wada-Hiraike, Osamu, Kawana, Kei, Kuramoto, Hiroyuki, McCormick, Frank, Aburatani, Hiroyuki, Yano, Tetsu, Kozuma, Shiro, Taketani, Yuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360787/ https://www.ncbi.nlm.nih.gov/pubmed/22662154 http://dx.doi.org/10.1371/journal.pone.0037431 |
Ejemplares similares
-
Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy
por: Lin, Shu-Fu, et al.
Publicado: (2012) -
Retinoblastoma cells activate the AKT pathway and are vulnerable to the PI3K/mTOR inhibitor NVP-BEZ235
por: Xie, Chencheng, et al.
Publicado: (2017) -
Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy
por: Li, Liangqing, et al.
Publicado: (2018) -
Antitumor Activity and Induction of TP53-Dependent Apoptosis toward Ovarian Clear Cell Adenocarcinoma by the Dual PI3K/mTOR Inhibitor DS-7423
por: Kashiyama, Tomoko, et al.
Publicado: (2014) -
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib
por: Roulin, Didier, et al.
Publicado: (2011)